Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study evaluating intravenous efgartigimod in acetylcholine receptor antibody seronegative generalized myasthenia gravis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis, gMG | Phase 3 | Status: ACTIVE_NOT_RECRUITING